Form 4: Cullinan CSO Sells Shares Under Pre-Planned 10b5-1

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported sales of common stock totaling 5,353 shares.

Summary

• Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), reported two separate sales of common stock.
• On February 23, 2026, 1,752 shares were sold at a weighted average price of $13.99 per share, with prices ranging from $13.68 to $14.31.
• This transaction was executed pursuant to a Rule 10b5-1 plan established on August 7, 2025.
• On February 24, 2026, an additional 3,601 shares were sold at a price of $14.47 per share.
• The second sale was specifically to cover personal income tax obligations arising from the vesting of restricted stock units.
• Following these transactions, Jennifer Michaelson beneficially owns 176,624 shares of Cullinan Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Insider sales under a 10b5-1 plan or for tax purposes are routine and typically do not reflect a change in the company's operational or financial outlook.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a pre-established Rule 10b5-1 plan or to cover tax obligations from vesting equity, are common and generally do not signal a change in the company's fundamental prospects. These are often routine liquidity events for executives.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine insider transactions, unlikely to signal a shift in company fundamentals.
• Employees: No direct impact indicated.

Key Dates

Recommendation

The reported insider sales by the Chief Scientific Officer are routine, consisting of transactions under a pre-established 10b5-1 plan and sales to cover tax obligations from vested equity. These types of sales do not typically indicate a change in the company's fundamental performance or future prospects, thus providing no new information to warrant a change in investment recommendation.

Keywords

Cullinan Therapeutics, CGEM, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief Scientific Officer, Jennifer Michaelson, Restricted Stock Units, Tax Obligations